Advancing bio-printing of living cells for regenerative medicine
Issued by European Commission · via EU Funding & Tenders Portal
- Published
- 18 Nov 2026
- Closes
- 16 Sept 2027
- Reference
- HORIZON-HLTH-2027-03-TOOL-02
- Location
- European Union
- Sector
- Healthcare & Pharma
This notice was amended
Details changed after publication. Re-check the official notice before bidding.
- Submission deadline changed from 22 Sept 2027 to 16 Sept 2027First seen by FreeTender on 1 Oct 2026 — most portals don’t publish when a corrigendum was issued.
At a glance
European Commission in European Union has published a funding call in healthcare & pharma: “Advancing bio-printing of living cells for regenerative medicine”. Submissions close on 16 September 2027, 302 days from today. Quote reference HORIZON-HLTH-2027-03-TOOL-02 in any correspondence with the buyer. FreeTender has recorded 423 notices from this buyer since 2026, 401 of them currently open. There are 34 open healthcare & pharma notices in European Union on FreeTender. Bids are submitted to the buyer through EU Funding & Tenders Portal, not through FreeTender.
Key requirements
Taken from the notice by FreeTender. The tender document on the official portal is binding — check it, and any corrigendum, before you bid.
To bid on EU public procurement
Most EU buyers ask for the European Single Procurement Document (ESPD) as a self-declaration with the bid. Submission is on the e-procurement platform named in the notice.
Details
Expected Outcome:
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Developing and using new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to most of the following expected outcomes:
- Biomedical scientists from academia and industry will gain access to entire bio-printing units designed to regenerate human tissue.
- Healthcare professionals acquire information on the safe and effective use of equipment enabling advanced therapies with bio-printed human tissue.
- Healthcare providers dispose of tools enabling them to treat conditions of unmet medical need.
- Individual patients will benefit from a personalised approach to their respective medical condition thanks to the bio-printed regenerative medicine solution.
Scope:
Tissue-specific functional 3D bio-printing of living cells has made significant progress as a new approach for transplantation applications in regenerative medicine. There are currently several types of bio-printing technologies under development for the repair of different targeted tissues or organs. To fully unleash the potential of bio-printed cell constructs for regenerative medicine several bottlenecks still need to be overcome. Various studies in pre-clinical models have shown that bio-printed cell constructs or tissues hold great promise for regenerative medicine, by allowing autologous tissue grafts being printed thus avoiding adverse graft-host reactions. However, translation of such approaches into clinical settings (i.e. humans) and their application to internal organs still needs to be investigated and demonstrated. Dependant on the actual target site (i.e. the defect tissue or organ in the human body) different bio-printing approaches may be preferable. For printing complex tissues and especially entire organs an in-vitro approach followed by transplantation is the preferred way. “In-situ” bio-printing, sometimes also referred to as “in-vivo”, or as “intraoperative”, reflects a bioprinting process performed on a live subject in a surgical setting and has in certain instances (e.g. tissue repair) advantages over an in-vitro bio-printing technique followed by transplantation. In-situ bio-printing involves direct patterning of bio-inks onto a patient’s body at the target site, allowing for precise construction of a site-matching tissue-structure within the actual physiological location where regeneration or repair is needed. As such, in-situ bio-printing allows for high adaptability, reduced risk of contamination, improved cell viability, function and host integration. The high cell densities present in the human vital organs underscore the importance of bio-inks which contain less additional biomaterials as matrix. Hence the bio-printing of cell constructs that comprise native tissue-like cell densities may facilitate repair and/or regeneration of defective complex tissues or internal organs. For such approaches meticulous engineering of the bio-printing equipment is necessary, involving sophisticated micro-surgical instrumentation and medical imaging platforms. To achieve the desired function and to mimic the natural cues in native tissues for in-vitro printed bio-constructs, the use of additional stimuli is needed, whereas in-situ approaches normally rely on the body as natural bioreactor providing the necessary extracellular cues. Recently, combinations of in-situ bio-printing with real-time stimuli have been investigated, even for the repair of internal organs. However, there remain bottlenecks that need to be overcome, like the integration with existing imaging modalities and surgical procedures or the long-time stability and functionality of the created bio-constructs. To address these challenges, researchers should work in multidisciplinary teams with engineers, biomedical scientists, cell biologists and medical doctors. Proposals should be based on the use of human cells and address all the following activities:
- Develop or improve existing bioprinting equipment that comprises all steps of the bio-printing suite to print bio-constructs with high cell-density for improved vascularisation and faster repair of the defect in the body.
- Scale-up the chosen bio-printing technology to a Good Manufacturing Practices (GMP) [1] conform/compliant manufacturing process.
- Perform all necessary regulatory work enabling the conduct of clinical studies and assess the clinical value of the developed bio-printing technology in first in-human studies.
Priority should be given to bio-printing approaches that either target vital internal organs followed by surgical grafting or employ in-situ approaches depositing the cell-laden bioink directly from the printhead or endoscope on the defect target site in the body. Regulatory knowledge of the field is desired and should be documented through contacts with relevant national or international European regulatory authorities. A good understanding of the different steps involved and the inherent risks in each of these steps will be a basis to identify appropriate safety and quality requirements. Requirements from the different established EU frameworks on Substances of Human Origin (SoHO), medical devices and pharmaceuticals including Advanced Therapy Medicinal Products (ATMPs) should be considered for manufacturing/preparation as well as for clinical outcome monitoring. A combination of requirements from different frameworks might be most appropriate to allow for responsible and fast uptake. Proposals under this topic may address any therapeutic area, i.e. any disease, dysfunction or defect. Sex differences at the cellular level should be taken into consideration. Preclinical stage and clinical development are eligible. The involvement of small and medium-sized enterprises (SMEs) [2] is encouraged. The European Commission's Joint Research Centre (JRC) may contribute to the proposals selected for funding with work on strategic technologies for economic security and innovative industrial ecosystems, particularly activities on innovation in vitro biotechnologies. Applicants should provide details of their clinical studies [3] in the dedicated annex using the template provided in the submission system. As proposals under this topic are expected to include clinical studies, the use of the template is strongly encouraged.
[1] https: //health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
[2] https: //eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32003H0361
[3] Please note that the definition of clinical studies (see introduction to this Work Programme part) is broad and it is recommended that you review it thoroughly before submitting your application.
Submissions open on 03 June 2027.
Part of call HORIZON-HLTH-2027-03
Type of action: HORIZON Research and Innovation Actions
Programme period: 2021 - 2027
Priorities: AI, DigitalAgenda
"> General conditions
1. Admissibility Conditions, proposal page limit and layout
Admissibility conditions are described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes. Proposal page limits and layout are described in Part B of the Application Form available in the Submission System.
2. Eligible Countries
Eligible countries are described in Annex B of the Work Programme General Annexes. A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide .
3. Other Eligibility Conditions
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible t
Context for bidders
We hold 423 notices from European Commission, going back to August 2026 — 401 of them still open. They buy mostly in IT & Telecom, Water & Environment and Forestry & Wildlife. There are 34 open Healthcare & Pharma tenders in European Union. This one closes in 302 days.
More from this buyer
- Impact of malicious use of Open-Source Intelligence on critical infrastructure business continuity· closes 4 Nov
- The impact of EU labour mobility on the Member States of the EU· closes 23 Sept
- Higher Voltage, Megawatt Charging System compatible, modular powertrain for Heavy Duty Vehicles (HDV) (2ZERO Partnership)· closes 14 Apr
- Large scale operational validation and upscaling of state-of-the-art (Generative) AI tools and models powering a next generation digital energy system· closes 31 Mar
- MSCA Staff Exchanges 2027· closes 13 Apr
Similar Healthcare & Pharma tenders
- Towards the next generation of frontier Artificial Intelligence models for healthcare· closes 16 Sept
- Improving socio-economic outcomes for persons with dementia and informal caregivers· closes 4 May
- Transforming the Health and Care Workforce for Sustainable and Resilient Systems· closes 21 Jan
- Towards a consolidated culture and creativity driven European innovation ecosystem· closes 23 Sept
- Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers· closes 16 Sept
Explore European Union
Before you bid on this tender
A quick checklist to help you decide whether to bid and prepare a compliant submission for this healthcare & pharma opportunity. Always verify the details on the official source.
- Confirm the exact closing date and time (and time zone) on the official portal — deadlines are strict and can be revised by a corrigendum.
- Read the full notice and every attached document, including the scope, specifications and any bill of quantities or terms of reference.
- Check the eligibility criteria — prior similar experience, annual turnover, certifications and registrations — and make sure you qualify before investing effort.
- Prepare any earnest-money deposit (EMD) or bid security and the required formats early; missing or wrongly-formatted documents are a common cause of rejection.
- Note how bids must be submitted (online or physical), in what format, and whether a digital signature or portal registration is required.
- Watch for corrigenda and clarifications right up to the deadline — requirements and dates can change.
More Healthcare & Pharma tenders
- Поставка лекарственных препаратов для медицинского применения (КЕТОРОЛАК)ДЕПАРТАМЕНТ КОНТРАКТНОЙ СИСТЕМЫ КУЗБАССА · Russia
- Поставка лекарственных препаратов для медицинского применения (МАГНИЯ СУЛЬФАТ)ДЕПАРТАМЕНТ КОНТРАКТНОЙ СИСТЕМЫ КУЗБАССА · Russia
- Оказание услуг по проведению лабораторных исследований с целью осуществления производственного контроля в Филиале «Отделение в городе Нефтеюганске» на 2027 и 2028 годаКАЗЕННОЕ УЧРЕЖДЕНИЕ ХАНТЫ-МАНСИЙСКОГО АВТОНОМНОГО ОКРУГА - ЮГРЫ "БЮРО СУДЕБНО-МЕДИЦИНСКОЙ ЭКСПЕРТИЗЫ" · Russia
- Поставка медицинских изделий: Рулон марлевый тканыйГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ ЗДРАВООХРАНЕНИЯ "ЦЕНТРАЛЬНАЯ РАЙОННАЯ БОЛЬНИЦА АПШЕРОНСКОГО РАЙОНА" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ КРАСНОДАРСКОГО КРАЯ · Russia
- Оказание услуг по проведению лабораторных исследований с целью осуществления производственного контроля в филиале «Отделение в городе Югорске» на 2027 и 2028 годаКАЗЕННОЕ УЧРЕЖДЕНИЕ ХАНТЫ-МАНСИЙСКОГО АВТОНОМНОГО ОКРУГА - ЮГРЫ "БЮРО СУДЕБНО-МЕДИЦИНСКОЙ ЭКСПЕРТИЗЫ" · Russia
FreeTender mirrors this notice for reference. Verify the details and bid on the official portal.
Verify & apply on the official portal →